NASDAQ$TVTX
Travere Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Travere Therapeutics reported financial results for the second quarter of 2022.
Travere Therapeutics reported a total revenue of $54.2 million for the second quarter of 2022, consisting of $51.0 million in net product sales and $3.2 million in licensing and collaboration revenue. The company's cash, cash equivalents, and marketable securities totaled $553.2 million as of June 30, 2022.
- NDA for accelerated approval of sparsentan in IgA nephropathy (IgAN) accepted by the FDA and granted Priority Review with a PDUFA target action date of November 17, 2022.
- Total revenue for the second quarter 2022 was $54.2 million, consisting of $51.0 million in net product sales and $3.2 million in licensing and collaboration revenue.
- Net product sales for the second quarter of 2022 were $51.0 million, compared to $54.6 million for the same period in 2021.
- Cash, cash equivalents and marketable securities totaled $553.2 million as of June 30, 2022.
Headline financials
Revenue & EPS history
Travere · Revenue · Quarterly
$54.2M
Revenue by segment
Travere · $33.9M total across 2 segments · Q3 2023
- Tiopronin products$25.9M+2.0%76.3%
- FILSPARI$8.04M—23.7%
Forward guidance
Travere Therapeutics is focused on the potential approval and launch of sparsentan for IgAN, advancing its pipeline, and strengthening its leadership position in the rare disease community.
Tailwinds
- The FDA accepted for review Travere's NDA for sparsentan for the treatment of IgA nephropathy and granted priority review.
- Travere is making progress in building commercial capabilities to prepare for a potential launch of sparsentan.
- The DUPLEX Study of sparsentan in FSGS continues to progress, with two-year results expected in the first half of next year.
- Travere received Breakthrough Therapy Designation for its pegtibatinase program in HCU.
- Travere is working with regulators to align on the design of a pivotal program for pegtibatinase.
Headwinds
- There is no guarantee that the review process for the sparsentan IgAN NDA will remain on track for the FDA’s assigned target action date.
- There is no guarantee that the FDA will grant accelerated approval of sparsentan for IgAN within the assigned target action date, or at all.
- There is no guarantee that the DUPLEX Study will support an application for traditional review or that sparsentan will be approved for FSGS.
- There is also no guarantee that the results from the ongoing clinical study of pegtibatinase will be positive
- The Company faces risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-0.3%
Avg return
30 days after
49%
25 / 51 earnings
Positive
+16.6%
Q3 2025
Best reaction
-16.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | -5.1% | +2.8% | |
| Q4 2025 | +3.1% | +0.1% | -8.4% | |
| Q3 2025 | +16.6% | +13.7% | +19.4% | |
| Q1 2025 | +1.6% | -2.6% | -27.6% | |
| Q4 2024 | -6.8% | -10.8% | -12.9% | |
| Q3 2024 | -1.1% | -0.0% | +5.9% | |
| Q2 2024 | -5.7% | -6.7% | -0.7% | |
| Q1 2024 | +7.8% | +0.6% | +25.1% | |
| Q4 2023 | -0.6% | +0.4% | -9.2% | |
| Q3 2023 | -4.7% | -16.0% | +30.3% | |
| Q2 2023 | -6.6% | -6.7% | -10.5% | |
| Q1 2023 | +5.6% | +4.2% | +19.7% | |
| Q4 2022 | +6.9% | +6.2% | +0.0% | |
| Q3 2022 | +3.1% | +0.5% | -12.4% | |
| Q2 2022 | +16.0% | +16.2% | +13.5% | |
| Q1 2022 | -14.2% | -13.2% | -6.4% | |
| Q4 2021 | +2.9% | +2.1% | -3.3% | |
| Q3 2021 | +10.0% | +15.1% | +10.8% | |
| Q2 2021 | -2.4% | +0.5% | +52.7% | |
| Q1 2021 | -16.6% | -17.4% | -41.2% | |
| Q4 2020 | -5.3% | -12.4% | -19.0% | |
| Q3 2020 | +1.6% | +11.4% | +18.1% | |
| Q2 2020 | -1.6% | -4.1% | -4.3% | |
| Q1 2020 | +7.6% | +0.8% | -0.9% | |
| Q4 2019 | -16.7% | -10.3% | -21.4% | |
| Q3 2019 | +4.4% | +8.0% | +20.7% | |
| Q2 2019 | -11.4% | -2.7% | -34.0% | |
| Q1 2019 | -7.9% | -5.5% | -2.7% | |
| Q4 2018 | +5.6% | +4.3% | +7.7% | |
| Q3 2018 | +0.6% | +1.2% | -4.4% | |
| Q2 2018 | -4.4% | -4.2% | +2.4% | |
| Q1 2018 | -5.2% | -5.7% | +11.6% | |
| Q4 2017 | +5.4% | +5.2% | -5.8% | |
| Q3 2017 | -13.4% | -16.3% | -17.1% | |
| Q2 2017 | -0.1% | +7.6% | +15.8% | |
| Q1 2017 | -4.4% | -6.5% | -7.1% | |
| Q4 2016 | +1.5% | -0.6% | -13.2% | |
| Q3 2016 | -4.3% | -1.2% | +8.5% | |
| Q2 2016 | +1.4% | -1.9% | -13.6% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | -2.8% | — | — | |
| Q3 2015 | -10.0% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +5.8% | — | — | |
| Q4 2014 | +9.5% | — | — | |
| Q3 2014 | -14.4% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q4 2013 | +8.4% | — | — | |
| Q3 2013 | -5.8% | — | — | |
| Q2 2012 | -9.9% | — | — | |
| Q3 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro